IQVIA Holdings (IQV) Stock Overview
Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IQV Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IQVIA Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$186.82 |
| 52 Week High | US$247.05 |
| 52 Week Low | US$136.41 |
| Beta | 1.18 |
| 1 Month Change | 18.41% |
| 3 Month Change | 7.39% |
| 1 Year Change | 34.31% |
| 3 Year Change | -8.43% |
| 5 Year Change | -19.89% |
| Change since IPO | 343.65% |
Recent News & Updates
Narrative Update • May 31
IQV: Future Returns Will Depend On AI Trial Expansion And Execution Risk Balancing
Narrative Update on IQVIA Holdings The analyst price target for IQVIA Holdings has moved from $186.12 to $195.00, reflecting updated assumptions on discount rate, profit margin, and P/E, alongside recent research in which several firms reiterated constructive views on clinical trial activity, AI related cost savings, and the stock's valuation. Analyst Commentary Recent Street research on IQVIA Holdings has been mixed, with some bullish rating changes and initiations sitting alongside lower price targets from more cautious voices.Seeking Alpha • May 20
IQVIA: The Market May Be Missing The AI And Data Story
Summary IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion. Despite 4.7x net debt/EBITDA, robust free cash flow, aggressive buybacks, and hidden growth support a 60% upside to $275/share in 3 years. Read the full article on Seeking Alpha
Narrative Update • May 17
IQV: Data Scale And AI Adoption Will Support Earnings Reacceleration
Analysts have reduced the fair value estimate for IQVIA Holdings by about $3 to $228.60, reflecting updated views on slightly softer revenue growth and profit margins, while recent research continues to indicate supportive long term demand for clinical trial and data analytics capabilities. Analyst Commentary Recent Street research on IQVIA presents a mixed picture, with several firms trimming price targets while others highlight potential upside tied to execution and data assets.Analysis Article • May 08
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a pretty great week for IQVIA Holdings Inc. ( NYSE:IQV ) shareholders, with its shares surging 13% to US$179...Recent updates
Narrative Update • May 31
IQV: Future Returns Will Depend On AI Trial Expansion And Execution Risk Balancing
Narrative Update on IQVIA Holdings The analyst price target for IQVIA Holdings has moved from $186.12 to $195.00, reflecting updated assumptions on discount rate, profit margin, and P/E, alongside recent research in which several firms reiterated constructive views on clinical trial activity, AI related cost savings, and the stock's valuation. Analyst Commentary Recent Street research on IQVIA Holdings has been mixed, with some bullish rating changes and initiations sitting alongside lower price targets from more cautious voices.Seeking Alpha • May 20
IQVIA: The Market May Be Missing The AI And Data Story
Summary IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion. Despite 4.7x net debt/EBITDA, robust free cash flow, aggressive buybacks, and hidden growth support a 60% upside to $275/share in 3 years. Read the full article on Seeking AlphaNarrative Update • May 17
IQV: Data Scale And AI Adoption Will Support Earnings Reacceleration
Analysts have reduced the fair value estimate for IQVIA Holdings by about $3 to $228.60, reflecting updated views on slightly softer revenue growth and profit margins, while recent research continues to indicate supportive long term demand for clinical trial and data analytics capabilities. Analyst Commentary Recent Street research on IQVIA presents a mixed picture, with several firms trimming price targets while others highlight potential upside tied to execution and data assets.Analysis Article • May 08
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a pretty great week for IQVIA Holdings Inc. ( NYSE:IQV ) shareholders, with its shares surging 13% to US$179...Narrative Update • Apr 30
IQV: Future Returns Will Rely On AI Enabled Clinical Trial Expansion
IQVIA Holdings' analyst fair value estimate has been reset from $200.00 to about $186.12 as analysts factor in a mix of reduced price targets across several firms, alongside ongoing optimism around AI, clinical trial activity and the company's data analytics capabilities. Analyst Commentary Recent research updates on IQVIA show a split picture, with some firms increasing ratings or setting higher targets while several bearish analysts are trimming price targets and calling out execution and growth risks tied to AI and recent results.Narrative Update • Apr 16
IQV: Data And Clinical Trial Scale Will Support Earnings Reacceleration
The analyst price target for IQVIA Holdings has been reset from $250.00 to $231.60 as analysts factor in updated models after recent Q4 results, AI related uncertainties, and broader sector target cuts, while still highlighting the company’s data and clinical trial capabilities in several upgraded ratings. Analyst Commentary Recent research updates on IQVIA show a mix of optimism around the company’s data assets and clinical trial exposure, alongside caution as models are reset after Q4 results and AI related questions.Narrative Update • Apr 01
IQV: Future Returns Will Lean On AI Driven Clinical Trial Upswing
Narrative Update on IQVIA Holdings The analyst price target framework for IQVIA Holdings is unchanged at $200. Recent research points to modest adjustments in revenue growth, profit margin and future P/E assumptions, as analysts highlight the company's data analytics capabilities, AI related cost efficiencies in clinical trials and expectations for increased trial activity into 2026.Narrative Update • Mar 18
IQV: Future Returns Will Lean On AI Efficiencies In Clinical Trials
The updated analyst price target for IQVIA Holdings moves to $200 from $186.40 as analysts factor in slightly higher revenue growth, modestly stronger profit margins, and a higher assumed future P/E multiple supported by recent upgrades that highlight AI efficiencies and expected clinical trial activity. Analyst Commentary Recent Street research around IQVIA reflects a mix of renewed optimism and lingering caution.Narrative Update • Mar 04
IQV: Future Returns Will Balance Trial Upside With AI And Execution Risks
Analysts have trimmed their fair value estimate for IQVIA Holdings from about $223 to roughly $186, reflecting a shift to a lower assumed future P/E multiple and a slightly higher discount rate. They still see upside potential based on expected clinical trial activity and the company's data analytics capabilities.
Narrative Update • Feb 17
IQV: Stronger 2026 Demand Visibility Supports Backlog And Margin Improvement Potential
Analysts have trimmed their average 12 month price target for IQVIA by around $70 to reflect updated Q4 guidance, ongoing work to factor in potential long term AI risks for contract research organizations, and recalibrated expectations for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research shows a split view on IQVIA, with some firms trimming targets after Q4 guidance while others highlight areas where execution and demand trends still support a more constructive stance on the stock.Narrative Update • Feb 03
IQV: Stronger Demand Visibility And Healthier Pipeline Set Up Cleaner 2026 Earnings
Analysts have lifted their price targets on IQVIA Holdings by up to US$30, citing improved demand visibility into 2026, healthier book-to-bill and RFP pipelines, and expectations for modest margin expansion supported by automation and efficiencies. Analyst Commentary Bullish analysts are leaning positive on IQVIA Holdings, with several research notes pointing to a constructive setup into 2026.Narrative Update • Jan 20
IQV: Stronger Demand Visibility And Pipeline Clarity Will Support Cleaner Earnings By 2026
Analysts have lifted their fair value estimate for IQVIA Holdings to $290 from $273. This reflects higher Street price targets and views that demand visibility, pipeline clarity, and modest margin expansion support a slightly richer assumed future P/E multiple and refined growth and discount rate inputs.Analysis Article • Jan 09
IQVIA Holdings Inc.'s (NYSE:IQV) P/E Still Appears To Be Reasonable
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Narrative Update • Jan 06
IQV: Recovery In Research Services Will Support Cleaner Earnings Setup By 2026
Narrative Update: IQVIA Holdings (IQV) Analysts have raised their price target framework on IQVIA by about US$18 to approximately US$273. This reflects updated views that the company is moving past prior cancellations, has a clearer and more stable outlook into 2026, and is operating in what some see as a moderately improving market for its clinical and commercial research services, even as margin pressures and valuation continue to be watched closely.Narrative Update • Dec 19
IQV Will Balance Recovery In Cancellations With Ongoing Execution And Margin Risks
The analyst-derived fair value estimate for IQVIA Holdings has been raised from $168.00 to approximately $223.24 per share, as analysts point to improving cancellation trends, a clearer earnings reacceleration path, and a moderately better environment supporting higher long-term growth and valuation multiples. Analyst Commentary Recent Street research on IQVIA reflects a more constructive long term narrative, but with a notable split between bullish and more cautious views on the stock’s risk reward profile.Narrative Update • Dec 05
IQV: Easing Cancellations Will Drive Earnings Reacceleration Into 2026
The analyst price target for IQVIA Holdings has been raised modestly from $247.50 to $250.00, as analysts point to stabilizing cancellations, improving visibility into 2026 earnings growth, and expectations for a valuation re rate supported by a gradually strengthening operating environment. Analyst Commentary Recent Street research on IQVIA presents a balanced mix of optimism around the company’s medium-term growth setup and caution about nearer-term execution risks and market conditions.Narrative Update • Nov 21
IQV: Earnings Reacceleration Will Drive Outperformance Into 2026
Analysts have lifted their price target on IQVIA Holdings slightly from $246.84 to $247.50. They cite improving earnings momentum, greater business stability, and continued sector resilience as key supporting factors.Narrative Update • Nov 06
IQV: Margins and Market Visibility Will Drive Outperformance Versus Peers
The analyst price target for IQVIA Holdings has been raised from $223.42 to $246.84. Analysts point to stabilizing profit margins, modestly higher growth expectations, and increasing industry confidence as key drivers of the upward revision.Narrative Update • Oct 23
Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings
The analyst price target for IQVIA Holdings has increased by approximately $5 to $223, as analysts cite the company's business resilience, workforce stability, and diversified client base as key drivers for higher valuation. Analyst Commentary Recent analyst updates highlight a mix of confidence and caution regarding IQVIA Holdings' future outlook, referencing the company's performance, client diversification, and sector positioning.Narrative Update • Oct 08
NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Analysts have slightly increased their price target for IQVIA Holdings from approximately $215.89 to $218.26. They cite improved demand momentum, strong segment performance, and business resilience relative to peers as reasons for the adjustment.Narrative Update • Sep 11
NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Analysts have modestly raised IQVIA’s price target to $215.89, citing strong B2B metrics, business diversification, and resilience in core segments despite sector headwinds and macroeconomic uncertainty. Analyst Commentary Bullish analysts cite IQVIA’s stronger business-to-business metrics, workforce stability, and lower customer concentration as reasons for outperformance and insulation against pharma sector restructurings, supporting higher valuation multiples.Analysis Article • Jul 24
Earnings Tell The Story For IQVIA Holdings Inc. (NYSE:IQV) As Its Stock Soars 25%
The IQVIA Holdings Inc. ( NYSE:IQV ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • Jul 17
At US$159, Is It Time To Put IQVIA Holdings Inc. (NYSE:IQV) On Your Watch List?
IQVIA Holdings Inc. ( NYSE:IQV ) saw a double-digit share price rise of over 10% in the past couple of months on the...Analysis Article • Jun 29
We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 16
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
Summary IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years. Between 2022 and 2028, the global data and analytics market that serves the biopharmaceutical sector will grow at a 9.5% CAGR. Read the full article on Seeking AlphaSeeking Alpha • Dec 12
IQVIA: Will This Beaten-Down Stock Bounce Back? 3 Things To Know
Summary IQVIA is trading at 18.2x, which is a discount compared to the industry average of 35.2x. IQV has better operating margins, operational efficiency, strong cash flows, and moderate leverage. The life sciences industry is going through an increased volume of clinical trial delays and cancellations across all therapeutic areas. Read the full article on Seeking AlphaSeeking Alpha • Aug 20
Reiterating Buy On IQVIA After Q2 Earnings
Summary IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains. Read the full article on Seeking AlphaSeeking Alpha • May 27
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
Summary There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production. Read the full article on Seeking AlphaShareholder Returns
| IQV | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 11.3% | 9.4% | 1.6% |
| 1Y | 34.3% | 17.1% | 28.2% |
Return vs Industry: IQV exceeded the US Life Sciences industry which returned 17.1% over the past year.
Return vs Market: IQV exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| IQV volatility | |
|---|---|
| IQV Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IQV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IQV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 93,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Inc. Fundamentals Summary
| IQV fundamental statistics | |
|---|---|
| Market cap | US$30.41b |
| Earnings (TTM) | US$1.39b |
| Revenue (TTM) | US$16.63b |
22.5x
P/E Ratio1.9x
P/S RatioIs IQV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQV income statement (TTM) | |
|---|---|
| Revenue | US$16.63b |
| Cost of Revenue | US$11.15b |
| Gross Profit | US$5.49b |
| Other Expenses | US$4.10b |
| Earnings | US$1.39b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.30 |
| Gross Margin | 32.99% |
| Net Profit Margin | 8.33% |
| Debt/Equity Ratio | 249.9% |
How did IQV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 09:11 |
| End of Day Share Price | 2026/06/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IQVIA Holdings Inc. is covered by 34 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |